Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 115Myelodysplastic Syndromes 109Precursor Cell Lymphoblastic Leukemia-Lymphoma 95Leukemia 74Hodgkin Disease 73Leukemia, Lymphocytic, Chronic, B-Cell 72Multiple Myeloma 71Lymphoma, Non-Hodgkin 71Lymphoma 66Myeloproliferative Disorders 54Graft vs Host Disease 50Lymphoma, Follicular 49Lymphoma, Mantle-Cell 47Leukemia, Myeloid, Accelerated Phase 47Lymphoma, Large B-Cell, Diffuse 46Congenital Abnormalities 46Leukemia, Myelomonocytic, Chronic 44Lymphoma, B-Cell, Marginal Zone 43Hematologic Neoplasms 43Leukemia, Myelogenous, Chronic, BCR-ABL Positive 42Leukemia, Myeloid, Chronic-Phase 41Burkitt Lymphoma 40Primary Myelofibrosis 39Blast Crisis 38Neoplasms, Plasma Cell 37Lymphoma, Large-Cell, Immunoblastic 32Waldenstrom Macroglobulinemia 25Myelodysplastic-Myeloproliferative Diseases 24Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 24Lymphoma, T-Cell, Cutaneous 23

Interventions

Docetaxel 171Radiotherapy 144Magnetic Resonance Spectroscopy 142Leuprolide 112Prednisone 108enzalutamide 102Radiosurgery 101Abiraterone Acetate 94Androgen Antagonists 91Goserelin 83bicalutamide 81gallium 68 PSMA-11 70Surveys and Questionnaires 63apalutamide 57Specimen Handling 56acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 55Radiation 47Gonadotropin-Releasing Hormone 45Standard of Care 44Biopsy 44Brachytherapy 42Radiotherapy, Intensity-Modulated 40Blood Specimen Collection 40darolutamide 39abiraterone 39cabazitaxel 35Exercise 35Carboplatin 33Pluvicto 32Triptorelin Pamoate 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Prostatic Neoplasms × Tacrolimus × Clear all
NCT00922129 2014-01-14

Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer

St. Joseph's Healthcare Hamilton

Phase 2/3 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡